Anti-IRS1 (phospho Y632) 抗体 [EPR259(2)] (ab109543)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR259(2)] to IRS1 (phospho Y632)
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-IRS1 (phospho Y632) antibody [EPR259(2)]
IRS1 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR259(2)] to IRS1 (phospho Y632) -
由来種
Rabbit -
アプリケーション
適用あり: WBmore details
適用なし: Flow Cyt,ICC,IHC-P or IP -
種交差性
交差種: Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- 293T cell lysate
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 0.31% Sodium citrate, 0.175% Sodium chloride, 0.0172% EDTA, 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR259(2) -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab109543の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000 - 1/10000. Predicted molecular weight: 132 kDa.
|
特記事項 |
---|
WB
1/1000 - 1/10000. Predicted molecular weight: 132 kDa. |
ターゲット情報
-
機能
May mediate the control of various cellular processes by insulin. When phosphorylated by the insulin receptor binds specifically to various cellular proteins containing SH2 domains such as phosphatidylinositol 3-kinase p85 subunit or GRB2. Activates phosphatidylinositol 3-kinase when bound to the regulatory p85 subunit. -
関連疾患
Polymorphisms in IRS1 may be involved in the etiology of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. -
配列類似性
Contains 1 IRS-type PTB domain.
Contains 1 PH domain. -
翻訳後修飾
Serine phosphorylation of IRS1 is a mechanism for insulin resistance. Ser-312 phosphorylation inhibits insulin action through disruption of IRS1 interaction with the insulin receptor.
Phosphorylation of Tyr-896 is required for GRB2-binding. - Information by UniProt
-
参照データベース
- Entrez Gene: 3667 Human
- Omim: 147545 Human
- SwissProt: P35568 Human
- Unigene: 471508 Human
-
別名
- HIRS 1 antibody
- HIRS1 antibody
- Insulin receptor substrate 1 antibody
see all
画像
-
All lanes : Anti-IRS1 (phospho Y632) antibody [EPR259(2)] (ab109543) at 1/1000 dilution
Lane 1 : 293T cell lysate, untreated
Lane 2 : 293T cell lysate treated with Alkaline Phosphatase
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP-labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 132 kDa
データシートおよび資料
-
Datasheet download
参考文献 (3)
ab109543 は 3 報の論文で使用されています。
- Zong J et al. Bromodomain-containing protein 2 promotes lipolysis via ERK/HSL signalling pathway in white adipose tissue of mice. Gen Comp Endocrinol 281:105-116 (2019). PubMed: 31121164
- Zhang J et al. Establishment of a novel hepatic steatosis cell model by Cas9/sgRNA-mediated DGK? gene knockout. Mol Med Rep 17:2169-2176 (2018). PubMed: 29207074
- Song Q et al. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells. Oncotarget 8:5003-5015 (2017). PubMed: 28002807